New drug tested in patients with liver disease

NCT ID NCT07428525

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the body processes a single dose of the drug AMG 133 in people with different levels of liver impairment compared to those with healthy livers. Thirty-six adults took part, and researchers measured drug levels in the blood and checked for side effects. The goal is to guide safe dosing for future studies in patients with liver disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 133
What this could lead to: If successful, this study will help doctors understand how to dose AMG 133 safely in patients with liver disease.
What could go wrong: This is an early, small study (36 people) focused on drug levels, not on treating a disease. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Clinical Pharmacology Of Miami, LLC

Miami, Florida, 33172, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Panax Clinical Research

Miami Lakes, Florida, 33014-2811, United States
Pinnacle Clinical Research San Antonio

San Antonio, Texas, 78229-4801, United States
The Texas Liver Institute, Inc.

San Antonio, Texas, 78215-2100, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.